Edgewise Therapeutics, Inc.’s EWTX share price has surged by 7.97%, which has investors questioning if this is right time to sell.

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...